BRAIN Biotech AG (ETR:BNN)

Market Cap	46.97M
Revenue (ttm)	53.52M
Net Income (ttm)	-13.66M
Shares Out	21.85M
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,641
Average Volume	9,644
Open	2.310
Previous Close	2.210
Day's Range	2.150 - 2.310
52-Week Range	1.420 - 4.400
Beta	0.79
RSI	52.22
Earnings Date	Aug 28, 2025

About Verve Therapeutics

BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. It operates through three segments: BioProducts, BioScience, and BioIncubator. The company offers enzymes, biocatalysts, microorganisms, and other bioactive natural compounds to produce foodstuffs and animal feed, cosmetics, and medical products, as well as for industrial applications in chemical companies, waste and hazardous materials disposal, and energy and raw materials production. The company was forme...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1993
• Employees: 318
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: BNN

Financial Performance

In 2024, BRAIN Biotech AG's revenue was 55.50 million, a decrease of -1.29% compared to the previous year's 56.23 million. Losses were -11.13 million, 34.4% more than in 2023.